scholarly journals The KLF6 splice variant KLF6-SV1 promotes proliferation and invasion of non-small cell lung cancer by up-regultating PI3K-AKT signaling pathway

2019 ◽  
Vol 10 (22) ◽  
pp. 5324-5331
Author(s):  
Nan Zhang ◽  
Qian-Qian Yan ◽  
Lu Lu ◽  
Jing-Bo Shao ◽  
Zhi-Gang Sun
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Signaling Pathway ◽  
Cell Lung Cancer ◽  
Splice Variant ◽  
Akt Signaling ◽  
Small Cell ◽  
Akt Signaling Pathway ◽  
Small Cell Lung ◽  
Proliferation And Invasion

AKT signaling pathway activated by HIN-1 methylation in non-small cell lung cancer

Tumor Biology ◽  
2011 ◽  
Vol 33 (2) ◽  
pp. 307-314 ◽  
Author(s):  
Yuanzi Yu ◽  
Dongtao Yin ◽  
Mohammad O. Hoque ◽  
Baoping Cao ◽  
Yan Jia ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Signaling Pathway ◽  
Cell Lung Cancer ◽  
Akt Signaling ◽  
Small Cell ◽  
Akt Signaling Pathway ◽  
Small Cell Lung

scholarly journals Anti-tumor activity of Shikonin against afatinib resistant non-small cell lung cancer via negative regulation of PI3K/Akt signaling pathway

2018 ◽  
Vol 38 (6) ◽  
Author(s):  
Baiying Li ◽  
Zuguo Yuan ◽  
Jin Jiang ◽  
Yuanquan Rao
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Signaling Pathway ◽  
Cell Lung Cancer ◽  
Akt Signaling ◽  
Small Cell ◽  
Nsclc Cell Line ◽  
Akt Signaling Pathway ◽  
Small Cell Lung ◽  
Anti Cancer

Acquired resistance of afatinib is a significant challenge for non-small cell lung cancer (NSCLC) therapy and the mechanisms remain unclear. Aberrant activation of epidermal growth factor receptor (EGFR)-dependent downstream pathways, especially phosphatidylinositol-3-kinases/protein kinase B (PI3K/Akt) signaling pathway has been reported to be involved in the occurrence of afatinib resistance. Developing effective anti-cancer agents to overcome afatinib resistance by targetting PI3K/Akt signaling pathway will be a potential strategy for NSCLC treatment. Shikonin is a naphthoquinone compound isolated from the roots of Lithospermum erythrorhizon. In the present study, the anti-cancer activity of Shikonin was evaluated on afatinib-resistant NSCLC in vitro and in vivo. The data showed that Shikonin inhibited the proliferation and induced apoptosis of afatinib-resistant NSCLC cell line by activating apoptosis signaling pathway and negatively regulating PI3K/Akt signaling pathway. These results revealed that Shikonin was a potential apoptosis inducer in afatinib-resistant NSCLC and a promising candidate for treating patients clinically.

Sign in / Sign up

Export Citation Format

Share Document